

Severe Acute Respiratory Syndrome in Association with Human Leukocyte Antigen and Clinical Implications

Attapon Cheepsattayakorn*

Zonal Tuberculosis and Chest Disease Center, Thailand

Human leukocyte antigen (HLA) is the most polymorphic genetic system in humans, with numerous alleles, and subsequently, various possible combinations [1]. These genes, the products of histocompatibility complex (MHC) [2] are located in the short arm of chromosome 6 at band p 21.3 [2] and are divided into three classes, I, II and III [1]. HLA class I is responsible for coding the molecules HLA-A, -B and -C, present in almost all somatic cells with killing of viral infected targets by class I antigens restrict cytotoxic T-cell (CD8+) function [2] while HLA class II genes code the molecules HLA-DR, -DQ and -DP [1] by presentation of exogenous antigens to T-helper cells (CD4+) or antigen presenting cells (APC) [2]. This polymorphism contributes to the differences in susceptibility to diseases among genetically distinct groups [1]. The molecules coded for by the HLA system are responsible for the antigen presentation [1]. The T lymphocytes that are linked to HLA molecules only recognize antigens by the antigen-specific cell surface receptor-antigens interaction [2], thus the HLA antigens [1] and MCH molecules [2] apparently participate in controlling susceptibility and resistance to various diseases. Some infectious diseases were considered as familial before the finding of the causative microorganism and early twin studies indicated that there was a substantial host genetic influence on susceptibility to diseases such as polio and tuberculosis (TB) [3]. At present, it has been confirmed that human genetic variation demonstrates a major influence on the course of diseases caused by several infectious microorganisms [3].

Itoyama reported that the deletion of the 287 bp *Alu* repeat (D allele) in intron 16 of the angiotensin converting enzyme 2 (*ACE 2*) gene is associated with hypoxemia and diffuse alveolar damage in patients with severe acute respiratory syndrome (SARS) [4] and may protect acute lung injury and respiratory failure [5]. Nevertheless, there may be potential confounders to a genetic association study as the following: 1) the dead patients were excluded from this study, 2) hypoxemia was defined as requiring oxygen supplementation, and 3) only 44 patients were studied [6]. Some HLA subtypes, particularly *HLA-B*0703* and *HLA-DRB1*0301* alleles have been demonstrated to be more prevalent in patients with SARS [7] and those with poorer outcomes [8]. On the other hand, the polymorphism in *ACE II* gene, coding for a functional receptor of the SARS-coronavirus, was not associated with the susceptibility or outcome of SARS [9]. A previous study revealed that *CXCL10(-938AA)* gene is always protective from SARS infection whenever it appears only jointly with either *Fg12(+158T/*)* or *HO-1(-497A/*)*, whereas *Fg12(+158T/*)* is associated with higher SARS-infection susceptibility unless combined with *CXCL10/IP-10(-938AA)* which is associated with lower susceptibility [10]. Chan concluded that the *ACE I/D* polymorphism was not directly associated with increasing susceptibility to SARS-coronavirus infection and was not associated with poor outcome after SARS-coronavirus infection [6]. A recent study in Taiwan demonstrated that *HLA-Cw*1502* [11], *-DR*0301* [11], and *-A*2402* [12] alleles conferred resistance against SARS infection. *CD209L* homozygote individuals [13] and low-mannose-binding-lectin-producing genotypes [14] have been demonstrated to have a significantly lower risk and increased risk of SARS infection, respectively. A previous study among Vietnamese population with SARS revealed that polymorphisms of two interferon-inducible genes,

2',5'-oligoadenylate synthetase 1 (OAS-1) (G-allele in exon 3 and the one in exon 6)) and *myxovirus resistance-A (MxA)* were associated with SARS infection [15]. The single nucleotide polymorphisms (SNPs) in *MxA* was associated with the progression of SARS [15]. The SNPs in *OAS-1* were associated with SARS-coronavirus infection or SARS development [15]. The GG genotype and G-allele of G/T-SNP at position -88 in the *MxA* gene promoter were demonstrated more frequent in hypoxemic group of patients with SARS than non-hypoxemic group [15]. They may be related to the response of SARS patients to interferons (IFNs), particularly those with AA genotype of the A/G-SNP in exon 3 of *OAS-1* may respond to IFN treatment more effectively than those with AG or GG genotype [15]. If SARS re-emerges, IFN could be a promising candidate to treat patients with SARS [16-23]. These findings may contribute to the perception of IFN-induced antiviral response to SARS infection. SARS-coronavirus infection elicited both CD4+ and CD8+ T-cell responses to the M protein in recovered SARS patients that persisted for a long period of time [24]. This may have significant implications in developing SARS vaccines [24]. A previous study indicated that a *HLA-A*0201*-restricted decameric epitope P15 (S411-420, KLPDDFMGCV) derived from the S protein that was found to localized within the angiotensin-converting enzyme 2 receptor-binding region of the S1 domain could significantly enhance the expression of *HLA-A*0201* molecules on the T2 cell surface [25]. P15 then stimulated IFN- γ -producing cytotoxic-T lymphocytes (CTLs) from the peripheral blood mononuclear cells of former SARS patients and induced specific CTLs from P15-immunized *HLA-A*2.1*-transgenic mice *in vivo* [25]. Significant P15-specific CTLs then were induced by *HLA-A*2.1*-transgenic mice that was immunized by a deoxyribonucleic-acid (DNA) vaccine encoding the S protein [25]. This suggested that P15 was a naturally processed epitope [25]. Thus, P15 could be a novel SARS-associated coronavirus-specific epitope and a potential target for evaluation of candidate SARS vaccines and characterization of virus control mechanisms [25].

References

1. Alves C, Souza T, Meyer I (2006) Immunogenetics and infectious diseases: special reference to the major histocompatibility complex. *Bra J Infect Dis* 10: 122-131.
2. Singh N, Agrawal S, Rastogi AK (1997) Infectious diseases and immunity: special reference response to major histocompatibility complex. *Emerg Infect Dis* 3: 42-49.

*Corresponding author: Attapon Cheepsattayakorn, Zonal Tuberculosis and Chest Disease Center, Thailand, Tel: 66-53-140767, 66-53-276364; Fax : 66-53-140773, 66-53-273590; E-mail: attaponche@yahoo.com

Received February 05, 2014; Accepted February 07, 2014; Published February 08, 2014

Citation: Cheepsattayakorn A (2014) Severe Acute Respiratory Syndrome in Association with Human Leukocyte Antigen and Clinical Implications. *Poul Fish Wildl Sci* 2: e106. doi:10.4172/2375-446X.1000e106

Copyright: © 2014 Cheepsattayakorn A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

3. Hill AVS (1999) Genetics and genomics of infectious disease susceptibility. *Br Med Bull* 55: 401-413.
4. Itoyama S, Keicho N, Quy T, Phi NC, Long HT, et al (2004) ACE1 polymorphism and progression of SARS. *Biochem Biophys Res Commun* 323: 1124-1129.
5. Kuba K, Imai Y, Rao S, Huan Y, Guo F, et al. (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* 11: 875-879.
6. Chan KCA, Tang NLS, Hui DSC, Chung GTY, Wu AKL, et al. (2005) Absence of association between angiotensin converting enzyme polymorphism and development of adult respiratory distress syndrome in patients with severe acute respiratory syndrome : a case control study. *BMC Infect Dis* 5: 26.
7. Ng MH, Lau KM, Li L, Cheng SH, Chan WY, et al. (2004) Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. *J Infect Dis* 190: 515-518.
8. Lin M, Tseng HK, Trejaut JA, Lee HL, Loo JH, et al. (2003) Association of HLA class I with severe acute respiratory syndrome coronavirus infection. *BMC Med Genet* 4: 9.
9. Chiu RWK, Tang NL, Hui DS, Chung GT, Chim SSC, et al. (2004) ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome. *Clin Chem* 50: 1683-1686.
10. Hsieh YH, Chen CWS, Schmitz SF H, King CC, Chen WJ, et al. (2009) Candidate genes associated with susceptibility for SARS-coronavirus. *Bull Math Biol* 72: 1.
11. Wang SF, Chen KH, Chen M, Li WY, Chen YJ, et al. (2011) Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection. *Viral Immunol* 24: 421-426.
12. Liu J, Wu P, Gao F, Qi J, Kawana-Tachikawa A, et al. (2012) Novel immune dominant peptide presentation strategy : a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein. *J Virol* 84: 11849-11857.
13. Chan VS, Chan KY, Chen Y, Poon LL, Cheung AN, et al. (2006) Homozygous LSIGN (CLEC4M) plays a protective role in SARS coronavirus infection. *Nat Genet* 38: 38-46.
14. Ip WK, Chan KH, Law HK, Tso GH, Kong EK, et al. (2005) Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. *J Infect Dis* 191: 1697-1704.
15. Hamano E, Hijikata M, Itoyama S, Quy T, Phi NC, et al. (2005) Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population. *Biochem Biophys Res Commun* 329: 1234-1239.
16. Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, et al. (2004) Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. *Nat Med* 10: 290-293.
17. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, et al. (2003) Treatment of SARS with human interferons. *Lancet* 362: 293-294.
18. Hensley LE, Fritzt LE, Jahrling PB, Karp CL, Huggins JW, et al. (2004) Interferon-beta 1a and SARS coronavirus replication. *Emerg Infect Dis* 10: 317-319.
19. Spiegel M, Pichlmair A, Muhlberger E, Haller O, Weber F (2004) The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein. *J Clin Virol* 30: 211-213.
20. Stroher U, DiCaro A, Li Y, Strong JE, Aoki F, et al. (2004) Severe acute respiratory syndrome-related coronavirus is inherited by interferon-alpha. *J Infect Dis* 189: 1164-1167.
21. Tan EL, Ooi EE, Lin CY, Tan HC, Ling AE, et al. (2004) Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. *Emerg Infect Dis* 10: 581-586.
22. Zheng B, He ML, Wong KL, Lum CT, Poon LL, et al. (2004) Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma). *J Interferon Cytokine Res* 24: 388-390.
23. Sainz JrB, Mossel EC, Peters CJ, Garry RF (2004) Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-Cov). *Virology* 329: 11-17.
24. Yang L, Peng H, Zhu Z, Gang L, Huang Z, et al. (2007) Persistent memory CD4+ and CD8+ T-cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigen. *J Gen Virol* 88: 2740-2748.
25. Zhou M, Xu D, Li X, Li H, Shan M, et al. (2006) Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes. *J Immunol* 177: 2138-2145.